Wrapping up its ninth year, CHI’s Immunogenicity and Bioassay Summit was host to industry, academia and regulatory authorities who shared new ways of overcoming immunogenicity and bioassay challenges at 3 co-located conferences, 4 short courses, 2 training seminars and the Bioassays for Immuno-Oncology symposium. Cambridge Healthtech Institute (CHI) would like to thank all the speakers, attendees, sponsors, and exhibitors for their participation. The 2017 summit featured:

• 300 Delegates from 165 Companies
• 75 Scientific Presentations & Case Studies, including FDA
• 25 Poster Presentations
• 20 Countries Represented
• 16 Exhibitors

View the 2017 Attendee List

If you missed our 2017 event, you can reserve a copy of the conference proceedings CD to access the speakers’ slides and poster abstracts our delegates received on-site.

2017 Keynote & Featured Speakers

Viswanath Devanarayan, Ph.D.

Adjunct Professor, University of Illinois at Chicago

Executive Director and Head, Global Statistics, Charles River Labs

Susan Kirshner, Ph.D.

Associate Chief, Immunology Lab, Therapeutic Proteins, Biotechnology

FDA/CDER

Thomas Little, Ph.D.

President, Bioassay Sciences

Thomas A. Little Consulting

Sofie Pattijn

Chief Technology Officer

ImmunXperts

Joao Pedras-Vasconcelos, Ph.D.

Biotech Quality and Immunogenicity Reviewer, Biotechnology Products

CDER-FDA

Amy S. Rosenberg, M.D.

Division Director, Office of Biotechnology Products

FDA/CDER

Perceval Sondag

Senior Statistician, Non-Clinical Statistics

Arlenda

Testimonials

“This conference provides very deep and broad scientific presentations, roundtable discussions, and excellent networking opportunities for scientists, managers/directors, CROs, vendors and consultants.”
- Senior Group Leader, Pfizer

“The Immunogenicity and Bioassay Summit covers up-to-date research and regulatory advances on all aspects of immunogenicity. It’s a very good meeting for experts and newcomers to the field.”
- Senior Director, Head, Bioanalytical and Biomarker Development, Research & Nonclinical Development, Shire

“Program and participants first class.”
- Associate Director, Novo Nordisk

“Great to get regulatory perspectives on challenges and expectations. The higher level strategic discussions were very informative.”
- Beth Arnold, Director, Biologics & Vaccine Bioanalytics, Merck

“Breakout interaction with FDA experts was very valuable.”
- Associate Director, Alexion Pharmaceuticals Inc.

View more testimonials